AI-native TechBio company Cellular Intelligence announced on Monday that it has acquired global rights to a clinical-stage cell therapy programme for Parkinson's disease from Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO).
Cellular Intelligence says that it intends to apply its proprietary AI platform to accelerate clinical development, manufacturing and the path to commercialisation. Novo Nordisk will make an equity investment in the company, while remaining eligible for future milestones and royalties.
Through this agreement, Cellular Intelligence aims to advance the continued clinical development of the cell therapy Parkinson's programme and deliver a disease-modifying therapy for people living with Parkinson's disease.
The programme covers an allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy, currently in a first-in-human Phase 1/2 clinical trial. It has received FDA Fast Track Designation, as well as IND clearance for further clinical development.
Mabwell's clinical trial application for 9MW5211 cleared by US FDA
Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC
European Commission approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
BioArctic and Eisai report FDA extension of Leqembi Iqlik review
Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD
Altasciences and Certara form strategic partnership to accelerate early drug development
ZYUS Life Sciences receives second US pain management patent